Goldman Sachs
CLVS

Goldman Sachs’s Clovis Oncology, Inc. CLVS Stock Holding History

Goldman Sachs’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-248,000
Closed -$1.74M – 6689
2021
Q1 		$1.74M Hold
248,000
– – ﹤0.01% 4125
2020
Q4 		$1.19M Buy
+248,000
New +$1.25M ﹤0.01% 4084
2020
Q2 		– Sell
-532,600
Closed -$3.39M – 5569
2020
Q1 		$3.39M Buy
532,600
+152,600
+40% +$1.22M ﹤0.01% 2940
2019
Q4 		$3.96M Buy
380,000
+279,300
+277% +$2.03M ﹤0.01% 3146
2019
Q3 		$396K Buy
+100,700
New +$815K ﹤0.01% 4554
2019
Q1 		– Sell
-40,000
Closed -$718K – 5545
2018
Q4 		$718K Buy
+40,000
New +$817K ﹤0.01% 4162
2018
Q2 		– Sell
-16,000
Closed -$845K – 6129
2018
Q1 		$845K Sell
16,000
-59,000
-79% -$3.44M ﹤0.01% 4153
2017
Q4 		$5.1M Buy
+75,000
New +$5.24M ﹤0.01% 2996
2017
Q1 		– Sell
-47,600
Closed -$2.11M – 7079
2016
Q4 		$2.11M Hold
47,600
– – ﹤0.01% 3810
2016
Q3 		$1.72M Buy
47,600
+16,500
+53% +$354K ﹤0.01% 3961
2016
Q2 		$427K Hold
31,100
– – ﹤0.01% 4999
2016
Q1 		$597K Sell
31,100
-43,900
-59% -$929K ﹤0.01% 4572
2015
Q4 		$2.63M Buy
+75,000
New +$4.84M ﹤0.01% 3402
2015
Q2 		– Sell
-50,000
Closed -$3.71M – 7499
2015
Q1 		$3.71M Buy
+50,000
New +$3.53M ﹤0.01% 3184
2014
Q4 		– Sell
-40,500
Closed -$1.84M – 7374
2014
Q3 		$1.84M Buy
+40,500
New +$1.69M ﹤0.01% 4023
2014
Q2 		– Sell
-11,600
Closed -$804K – 7190
2014
Q1 		$804K Buy
+11,600
New +$852K ﹤0.01% 4881
2013
Q4 		– Sell
-47,300
Closed -$2.88M – 6841
2013
Q3 		$2.88M Buy
+47,300
New +$3.35M ﹤0.01% 3539

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $160M AUM 21.24% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Goldman Sachs's CLVS Position: Q4 2022 in Review

Goldman Sachs sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 139,904 shares — an estimated $166K sold.

Goldman Sachs first reported a position in CLVS in Q2 2013 and held it in 38 quarters. The position peaked at $65.4M in Q4 2015. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Goldman Sachs reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Goldman Sachs sold 139,904 Clovis Oncology, Inc. shares in Q4 2022, an estimated $166K.
  • Goldman Sachs first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 38 quarters.
  • Goldman Sachs's Clovis Oncology, Inc. position peaked at $65.4M in Q4 2015.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.